LSR as a Radioligand Therapy Target
LSR, lipolysis stimulated lipoprotein receptor, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, LSR staining is highest in bladder cancer (100% of samples positive), colorectal cancer (100% of samples positive) and ovarian cancer (100% of samples positive). Published literature reports that LSR internalizes after ligand binding, which helps retain a radionuclide inside tumor cells. Clinical status: Discovery-stage (no clinical drug program).
Is LSR a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in bladder cancer, 100% of samples positive.
- ✅ Internalization: Reported to internalize, which favors radionuclide retention.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
LSR expression in cancer
Protein expression of LSR across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Bladder Cancer | 0.89 | High | 100% |
| Colorectal Cancer | 0.83 | High | 100% |
| Ovarian Cancer | 0.83 | High | 100% |
| Cervical Cancer | 0.82 | High | 100% |
| Breast Cancer | 0.79 | High | 100% |
| Lung Cancer | 0.77 | High | 100% |
| Head and Neck Cancer | 0.75 | High | 100% |
| Thyroid Cancer | 0.75 | High | 100% |
| Lymphoma | 0.73 | High | 100% |
| Neuroendocrine Tumors | 0.67 | High | 100% |
| Prostate Cancer | 0.67 | High | 100% |
| Endometrial Cancer | 0.64 | High | 100% |
| Pancreatic Cancer | 0.58 | High | 100% |
| Gastric Cancer | 0.56 | High | 100% |
| Liver Cancer | 0.53 | High | 100% |
| Testicular Cancer | 0.50 | Medium | 100% |
| Skin Cancer | 0.44 | Medium | 92% |
| Glioma | 0.42 | Medium | 100% |
| Melanoma | 0.33 | Medium | 67% |
| Kidney Cancer | 0.30 | Medium | 91% |
Is LSR internalized?
Yes. The binding of Ib to LSR causes an oligomer formation of Ib in lipid rafts of plasma membranes, mediating the entry of Ia into the cytoplasm.
Sources: PMID 38133199 · PMID 30297616 · PMID 30044945 · PMID 27856957 · PMID 24990559. AI-extracted from abstracts, so verify before citing.
LSR clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for LSR yet. Search ClinicalTrials.gov for LSR trials.
LSR normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See LSR in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
LSR gene essentiality (DepMap)
CRISPR knockout effect across 1257 cancer cell lines: 0.14 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related bladder cancer radioligand targets
EGFR · HER3 (ERBB3) · c-MET (MET) · SSTR2 · ITGAV · HER2 (ERBB2) · B7-H3 (CD276) · FAP
See all radioligand therapy targets in bladder cancer.
See how LSR ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.